Bajaj Healthcare soars on launching Favipiravir tablets for COVID-19 treatment
Bajaj Healthcare jumped 11.56% to Rs 586.80 after the company announced the launch antiviral Favipiravir tablets, under the brand name Favijaj, for the treatment of mild to moderate COVID-19. In a regulatory filing made during market hours today, the company said that the tablets comprising Favipiravir in different dosage forms is used for the treatment of mild to moderate COVID-19 disease. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus. The company has successfully developed the active pharmaceutical ingred...